Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 1 month ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
The Asia Pacific Cardiovascular Research (ASPIRE) Network
Author(s): Clement Lau , Philip D Adamson , Nicholas Chew , et al Added: 4 months ago

Demographic

Guidelines & Statements
2 Trials That Will Change My Practice with Prof Rasha Al-Lamee
Author(s): Rasha Al-Lamee Added: 2 months ago
TCT 2025 - In this comprehensive highlights video from TCT 2025, Prof Rasha Al-Lamee (Imperial College Healthcare NHS Trust, UK) delivers an expert analysis of the groundbreaking late-breaking trials that are set to reshape interventional cardiology practice.Join Prof Al-Lamee as she breaks down the pivotal studies driving innovation in cardiovascular care and discusses their implications for… View more

Intervention
FLOW: Kidney, Cardiovascular, Mortality, Metabolic and Safety Results
Author(s): Richard Pratley Added: 1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
AHA 25: The OCEAN Trial
Author(s): Atul Verma Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter… View more

Anticoagulation

Electrophysiology & Arrhythmia
TCT 25: 5 Trials That Will Change My Practice with Dr Mirvat Alasnag
Author(s): Mirvat Alasnag Added: 2 months ago
TCT 2025 - In this insightful highlights video from TCT 2025, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) provides expert commentary on the most impactful late-breaking clinical trials presented at this year's conference.The commentary distills the most important late-breaking trials in structural cardiology, coronary interventions, and artificial intelligence presented at TCT 2025… View more

Digital Health

Guidelines & Statements
TCT 25: Seven-Year Follow-up of the PARTNER 3 Trial
Author(s): Michael J Mack Added: 2 months ago
TCT 2025 - Long-term follow-up of the PARTNER 3 trial showed no safety concerns for transcatheter aortic-valve replacement (TAVR) compared to surgical treatment of aortic stenosis (AS).Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes from the seven-year follow-up of the PARTNER 3 low-risk randomised trial (NCT02675114)… View more

Imaging & Diagnostics

Intervention
ESC 25: The SEMA-VR CardioLink-15 Trial
Author(s): Subodh Verma Added: 4 months ago
ESC Congress 2025 - The SEMA-VR CardioLink-15 trial revealed that semaglutide may enhance endogenous progenitor cell-mediated vasculogenic repair processes.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss the findings from the SEMA-VR CardioLink-15 trial. The study compared usual care with semaglutide, GLP-1RA for six months in 46 patients with either type 2 diabetes… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Hyperpolarised 13C MRI in Cardiovascular Disease
Author(s): Clement Lau , Redha Boubertakh , Jennifer A Bryant , et al Added: 3 days ago

Imaging & Diagnostics
AHA 24: 3 Trials That Will Change My Practice
Author(s): Michelle Kittleson Added: 1 year ago
AHA Conference 2024 - In this highlights video from AHA 2024, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, US) offers a concise and insightful summary of the most influential late-breaking trials presented at the conference. Dr Kittleson discusses the pivotal studies poised to impact clinical practice and enhance patient outcomes in heart failure care.Trials covered in detail… View more

Heart Failure

Prevention & Chronic Conditions